Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
102 hedge funds and large institutions have $128M invested in Y-mAbs Therapeutics in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 26 closing their positions.
1,800% more call options, than puts
Call options by funds: $171K | Put options by funds: $9K
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
0.59% less ownership
Funds ownership: 64.3% → 63.7% (-0.59%)
9% less funds holding
Funds holding: 112 → 102 (-10)
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
43% less capital invested
Capital invested by funds: $225M → $128M (-$97.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$3.34M |
| 2 |
Millennium Management
New York
|
+$2.5M |
| 3 |
ACA
Acorn Capital Advisors
New York
|
+$2.17M |
| 4 |
Morgan Stanley
New York
|
+$1.04M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$901K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.83M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.33M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.05M |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$1.83M |
| 5 |
BlackRock
New York
|
-$560K |
YMAB Hedge Fund Activity: Q1 2025 in Review
102 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2025, worth a combined $128M — down 43% from $225M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of YMAB and 16 opened new positions — a net loss of 10 holders — while 28 trimmed existing stakes and 40 added.
The largest buyer was Caligan Partners, adding an estimated $3.34M. The largest seller was Logos Global Management, exiting entirely with an estimated $7.83M sold.
- 102 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2025, down from 112 in Q4 2024.
- Funds reported $128M of Y-mAbs Therapeutics stock for Q1 2025, down 43% quarter-over-quarter.
- 16 funds opened new Y-mAbs Therapeutics positions in Q1 2025 and 26 closed out, a net change of -10 holders.
- The largest Y-mAbs Therapeutics buyer in Q1 2025 was Caligan Partners, an estimated $3.34M added.
- The largest Y-mAbs Therapeutics seller in Q1 2025 was Logos Global Management, an estimated $7.83M sold.
Based on aggregated 13F filings for Q1 2025.